This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Reviewing the FDA Breakthrough Device Designation for Roche's Elecsys® Amyloid Plasma Panel for Alzheimer's Disease detection

Ticker(s): RHHBY, LLY

Who's the expert?

Institution: University of Kansas

  • Director of NIH-funded University of Kansas Alzheimer's Disease Center.
  • Currently manages 300 patients with Alzheimer's disease.
  • Research is focused on brain energy metabolism, the role brain energy metabolism plays in Alzheimer's Disease, and how to manipulate brain energy metabolism.

Interview Questions
Q1.

Describe your background and practice setting

Added By: ben_admin
Q2.

How many patients with Alzheimer's disease do you manage?

Added By: ben_admin
Q3.

What is the gold standard for Alzheimer's diagnosis currently?

Added By: ben_admin
Q4.

What is your opinion on the potential of Roche's Amyloid Plasma Panel?

Added By: ben_admin
Q5.

What patients would you order this panel for?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.